Raising seed round Boston 2026: what the market data shows
Boston took 26.2% of US biotech venture dollars in 2025 and about 3% to 4% of AI and SaaS. That split decides whether your seed round is local or national.
Raising seed round Boston 2026: what the market data shows
Boston is a sector market, not a general startup market. Carta ranked it fourth among US ecosystems with 6.6% of venture dollars raised in 2025, and second in biotech at 26.2%. Raising a seed round in Boston works if your company is lab-adjacent. If you are pure software, plan a national process.
Boston's funding logic follows the universities and the hospitals rather than a general tech scene, and the sector splits below show it. That decides whether your round gets run from Kendall Square or from a Zoom window pointed at Sand Hill Road.
As of this refresh, August 2026, the most recent complete market data covers calendar year 2025. Carta, PitchBook, CB Insights and SVB publish annually and quarterly, not weekly, so every figure below carries the period it measures. Nothing here describes what happened last week.
Boston VC funding in one table
Five numbers decide where you run your process, each covering a specific slice of 2025. Read the period column before the figure.
| Metric | Figure | Period covered | Source |
|---|---|---|---|
| Boston's rank among US startup ecosystems | 4th, with 6.6% of venture dollars raised | Full-year 2025 | Carta |
| Boston's share of US biotech venture dollars | 26.2%, 2nd nationally | Full-year 2025 | Carta |
| Boston's share of US healthtech fundraising | 8.3%, 3rd nationally | Full-year 2025 | Carta |
| Boston's share of US cash raised in AI, SaaS, hardware, consumer | About 3% to 4% in each | Full-year 2025 | Carta |
| Massachusetts startup funding, all stages | $16.7B, up 12% over 2024 | Full-year 2025 | CB Insights |
The gap between 26.2% and 3% is the entire argument. In one year, one city was the second-largest biotech capital market in the country and a rounding error in AI.
Massachusetts startup funding is growing while the national round count is not. State venture capital reached $16.7 billion in 2025, up 12% over 2024 (CB Insights), while startups on Carta raised $119.5 billion across 4,859 new rounds in 2025, the lowest annual round count in at least six years (Carta). Fewer, larger rounds means a longer target list, not a shorter one.
What Boston seed investors actually back
The active Boston seed investors split into two populations that barely overlap. Software funds and life-science company builders read completely different decks.
- Underscore VC: Boston-based, focused on B2B software entrepreneurs at pre-seed and seed (Crunchbase).
- Boston Seed Capital: seed funding for internet-enabled businesses including e-commerce, fintech, marketplaces and SaaS (Crunchbase).
- Atlas Venture: Cambridge-based, creates and invests in biotech companies at seed and early stage (Crunchbase).
- Third Rock Ventures: Boston-based, invests in transformational life-science companies (Crunchbase).
- General Catalyst: Cambridge-based, seed through growth, emphasis on applied AI and complex industries (Crunchbase).
Do not send a B2B SaaS deck to Atlas or Third Rock, and do not pitch a therapeutics platform to Underscore. The two lists above do not overlap, and a mis-targeted intro burns the referrer more than it burns you.
Treat the company-creation firms as a relationship, not a form. Atlas creates biotech companies as well as investing in them, so the way in is scientific, through people who already know your work.
Boston biotech investors are selective, not open
Biotech capital recovered in 2025 and got harder to reach in the same year. Both halves sit in the same PitchBook data.
Global biopharma VC deal value rose to $33.8 billion in 2025, the second consecutive annual increase, while capital concentrated in fewer, larger financings (PitchBook). The quarterly view is rougher: biopharma startups attracted $5.4 billion across 198 VC deals in Q2 2025, both figures at multiyear lows (PitchBook).
Investors favored de-risked assets, late-stage NewCos and platforms addressing clearly defined biological bottlenecks, which made the 2025 recovery selective rather than broad-based (PitchBook). SVB's read of the same year matches: healthtech and medical devices stayed relatively stable while biopharma investment declined and diagnostics and tools faced pressure (SVB).
If your work has a real AI component, lead with it. US and European healthcare AI companies received nearly $18 billion in VC investment during 2025, which was 46% of all healthcare investment SVB tracked that year (SVB).
Unvalidated preclinical is the hardest seat in this market. Build the ask around the next translational milestone and the evidence that de-risks it, not around the breadth of the platform. The mechanics are in the biotech seed fundraising guide.
Boston vs SF fundraising: when to raise locally, when to widen
Your sector's Boston share is the decision rule, and full-year 2025 gives you the number.
| Your company | Boston's share of US dollars, full-year 2025 | Where to run the process |
|---|---|---|
| Biotech, therapeutics | 26.2%, 2nd nationally | Boston first. The local list is deep enough to fill a round |
| Healthtech | 8.3%, 3rd nationally | Boston plus a national list from week one |
| AI, SaaS, hardware, consumer | About 3% to 4% each | National from day one. Boston is a supplement |
All three shares are full-year 2025 figures (Carta).
If your sector took 3% to 4% of national dollars in Boston, a Boston-only investor list is a rounding error.
Reading that as "Boston is narrow" is the wrong lesson. It was one of only three US metros to rank in the top five for fundraising across all seven sectors Carta analyzed in 2025: AI, SaaS, hardware, biotech, healthtech, fintech and consumer (Carta). Rank and share answer different questions, and share is the one that tells you how many local checks exist. Widening the process never means dropping the local funds: a national list keeps Boston on it and adds the rest.
Where to point the outreach next
Market data tells you what is normal; it does not tell you which funds are actually deploying into your stage and sector right now. A sector share describes a year that has closed. The fund that led three seed rounds in your niche last quarter is a name, not a percentage.
Start from a matched list, not from a geography. For lab-adjacent companies, the US healthcare seed investors list and the deep tech seed VC list are closer to your real target set than any Boston directory. Causo matches you to the investors most likely to fund you and drafts the outreach, which is the part market data cannot do for you.
Check these figures against the current annual releases before planning around them. Everything here is anchored to full-year 2025.
FAQ
Which VCs invest in Boston startups? Boston's seed investors split by sector. On the software side, Underscore VC backs B2B software entrepreneurs at pre-seed and seed, and Boston Seed Capital funds internet-enabled businesses including e-commerce, fintech and SaaS, per their Crunchbase profiles. On the life-science side, Atlas Venture in Cambridge creates and invests in biotech companies, and Third Rock Ventures backs transformational life-science companies. Cambridge-based General Catalyst invests from seed through growth.
How much do Boston startups raise? Massachusetts startups raised $16.7 billion in venture capital during 2025, a 12% increase over 2024, according to CB Insights. Carta's 2025 ecosystem ranking put Boston fourth nationally, accounting for 6.6% of venture dollars raised that year. Both cover full-year 2025, the most recent complete data at the time of writing, and neither is a seed-only figure.
Is Boston good for biotech fundraising? By share of capital, yes: Boston-based startups captured 26.2% of all US biotech venture dollars in 2025 and ranked second nationally, per Carta. The caveat is selectivity. PitchBook reported global biopharma VC deal value of $33.8 billion in 2025, the second consecutive annual increase, with capital concentrating in fewer, larger financings and investors favoring de-risked assets.
What sectors dominate Boston venture? Life sciences dominate. Carta's full-year 2025 data put Boston second nationally in biotech with 26.2% of US biotech venture dollars and third in healthtech with 8.3% of US healthtech fundraising, while AI, SaaS, hardware and consumer each accounted for only about 3% to 4% of US cash raised. Boston still ranked top five across all seven sectors Carta analyzed.
Do Boston VCs invest at pre-seed and seed? Yes. Underscore VC focuses on B2B software entrepreneurs at the pre-seed and seed stages, Boston Seed Capital provides seed-stage funding for internet-enabled businesses, and Atlas Venture invests at seed and early stage in biotech, according to their Crunchbase profiles. General Catalyst supports companies from seed through growth, so one firm can sit on your seed list and reappear at Series C.
Related on the hub
- Seed raise Singapore 2026: EDBI, Temasek, and SEA routes — Related regional guide.
- Raising VC outside Silicon Valley: 2026 founder playbook — Related regional guide.
- European Startup Funding This Quarter: 2026 Data by Market — Related regional guide.
Run this raise inside Causo.
Match to the best-fit partner at 1,000+ funds, draft a hyper-specific email, and send from your own inbox, in one place.